NGAM Advisors L.P. decreased its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 3.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,778 shares of the medical research company’s stock after selling 1,629 shares during the period. NGAM Advisors L.P.’s holdings in PRA Health Sciences were worth $2,984,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its position in PRA Health Sciences by 144.0% in the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock worth $115,000 after buying an additional 906 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in PRA Health Sciences by 232.3% in the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock worth $121,000 after buying an additional 1,289 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in PRA Health Sciences during the first quarter worth $136,000. First Bank & Trust boosted its position in PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock worth $206,000 after buying an additional 54 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new position in PRA Health Sciences during the first quarter worth $208,000.

PRA Health Sciences, Inc. (PRAH) opened at 73.81 on Friday. The stock has a market capitalization of $4.62 billion, a PE ratio of 47.65 and a beta of 0.45. The company has a 50-day moving average price of $75.21 and a 200-day moving average price of $67.10. PRA Health Sciences, Inc. has a 12-month low of $48.42 and a 12-month high of $80.99.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The business had revenue of $457.90 million during the quarter, compared to analyst estimates of $447.79 million. During the same period in the previous year, the business posted $0.63 earnings per share. The firm’s revenue for the quarter was up .5% on a year-over-year basis. Analysts expect that PRA Health Sciences, Inc. will post $3.18 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/ngam-advisors-l-p-has-2-98-million-position-in-pra-health-sciences-inc-nasdaqprah/1472188.html.

A number of research analysts have recently weighed in on the company. Jefferies Group LLC set a $73.00 price objective on PRA Health Sciences and gave the company a “buy” rating in a research report on Thursday, June 1st. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of PRA Health Sciences in a research report on Wednesday. Bank of America Corporation assumed coverage on PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 price objective on the stock. Credit Suisse Group reaffirmed an “outperform” rating and set a $76.00 price objective (up from $69.00) on shares of PRA Health Sciences in a research report on Tuesday, June 6th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $93.00 price target (up from $90.00) on shares of PRA Health Sciences in a report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $78.00.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.